Previously Funded Research

The Myrovlytis Trust  has funded over £6 million of BHD research. You can see a selection of the funded research projects below.

Previous research projects funded by the Myrovlytis Trust

Professor Laura Schmidt, National Cancer Insitute, NIH, USA

Efficacy of AZZD8066 as Therapeutic Treatment of Kidney Tumors in the Nikon Rat, and Animal Model of BHD Syndrome.

Dr Tom Blundell, University of Cambridge, UK

To elucidate the structural definition of folliculin and its interacting proteins.

Elizabeth Henske, Harvard, USA

The Role of the Birt-Hogg-Dubé Protein in mTOR regulation.

Professor Eamon Maher and Professer Farida Latif, University of Birmingham, UK

To elucidate the molecular basis for Birt-Hogg-Dube syndrome and develop novel strategies for therapy by determining the functions of the folliculin protein by proteomic analysis and identification of interacting proteins and establishing a conditional mouse model of BHD.

Eric Miska, University of Cambridge, UK

Analysis of the kidney small Rnome in BHD and renal cell carcinoma.

Dr Timothy Cash, University of Pennsylvania, USA

Role of Birt-Hogg-Dube tumor suppressor in embryonic development.

Professor Maria Czyzyk-Krzeska

Tumour Supressor Networks: Regulation of FLCN expression by VHL in renal cancer.

Dr Andy Tee, University of Cardiff, UK

Identifying therapies and drug targets for treatment of Birt-Hogg-Dubé syndrome.

Dr Stéphane Richard

Functional analysis of novel missense FLCN variants identified in patients affected with Bitr-Hogg-Dubé syndrome or isolated renal cancer.

Dr Derek Lim, University of Birmingham, UK

International Clinical Genetic and Therapeutic Study of Birt-Hogg-Dubé Syndrome.

Dr Maurice van Steensal, Maastricht University Medical Centre, The Netherlands

Topical rapamycin to treat fibrofolliculomas in Birt-Hogg-Dubé syndrome.

Dr Arnim Pause, McGill University, Canada

Investigating the mechanism of action of the BHD//Folliculin tumour suppressor protein.

Dr Yosef S. Haviv, Hadassah Medical Organisation, Israel

An SV-40-based kidney gene therapy approach for Birt-Hogg-Dubé syndrome.

Dr Andrew Baker

Development of virus and cell-based targeting platforms for renal gene therapy.

Dr Richard Paul Harbottle

Utilising Non-Viral S/MAR Plasmid Vectors to Develop Prophylactic Gene Therapy for Birt-Hogg-Dubé Syndrome.

Dr Vera Krymskaya

Regulation of the TFE3 transcriptional activity by FLCN, FNIP and AMPK; TFE3 and AMPK as therapeutic targets for BHD syndrome.

Dr Kyle Furge

Evaluation of a mitochondrial modulating drug (MK-886) in the prevention of FLCN-associated renal tumors.

Memberships